AJJ Medtech Holdings Limited: FY2025 Financial Review & Analysis
AJJ Medtech Holdings Limited has released its audited financial statements for the year ended 31 December 2025, highlighting adjustments made to its previously announced unaudited results. This article reviews the key financial metrics, examines the nature and implications of the adjustments, and offers investors a clear perspective on the company’s financial position and outlook.
Key Financial Metrics
| Metric |
FY2025 (Audited) |
FY2025 (Unaudited) |
YoY Change |
| Revenue |
S\$3,192k |
S\$3,192k |
N/A |
| Cost of Sales |
S\$2,017k |
S\$2,017k |
N/A |
| Gross Profit |
S\$1,175k |
S\$1,175k |
N/A |
| Selling & Distribution Expenses |
S\$482k |
S\$692k |
N/A |
| Administrative Expenses |
S\$3,631k |
S\$3,421k |
N/A |
| Finance Costs |
S\$87k |
S\$87k |
N/A |
| Loss Before Tax |
S\$2,928k |
S\$2,928k |
N/A |
| Net Loss (Attributable to Equity Holders) |
S\$2,931k |
S\$2,931k |
N/A |
| Cash & Cash Equivalents |
S\$414k |
S\$414k |
N/A |
| Total Assets |
S\$3,545k |
S\$3,627k |
N/A |
| Total Liabilities |
S\$6,258k |
S\$6,340k |
N/A |
| (Capital Deficiency)/Equity |
S\$(2,713k) |
S\$(2,713k) |
N/A |
Note: The report does not provide prior year or quarter data, so YoY and QoQ comparisons are not available. No dividend information is disclosed.
Material Differences and Adjustments
-
Reclassification of Expenses: Administrative expenses decreased while selling and distribution expenses increased due to a reclassification, with no impact on overall loss.
-
Investment in Subsidiaries: An increase was recorded in the Company’s investment in subsidiaries due to equity-settled share-based payments to subsidiary employees.
-
Factoring Arrangements and Receivables: Adjustments were made to the classification and presentation of factoring arrangements, affecting trade and other receivables.
-
Loans and Related Party Balances: Significant reclassification between current and non-current liabilities, particularly amounts due to key management personnel and directors.
-
Cash Flow Statement Adjustments: Presentational refinements, including gross presentation of loans from/to directors and factoring arrangements.
Errors, Inconsistencies & Exceptional Items
-
All material differences were presentational or related to classification, and did not impact the underlying business operations, cash flows, or financial position.
-
No exceptional earnings or expenses, asset revaluations, or delayed recognition of items were disclosed.
Historical Performance Trends
There is no data provided on previous years or quarters, so trends cannot be assessed. The company continues to report operating losses and capital deficiency, indicating ongoing financial challenges.
Corporate Actions & Related Party Transactions
-
Share Award Plan: Share-based payment awards were granted to subsidiary employees, increasing investment in subsidiaries.
-
Loans from Directors: Notable fund flows involving loans from directors, which were grossed up for cash flow presentation.
-
Share Issuance: The company issued new ordinary shares, net of share issue expenses, raising S\$869k.
Directors’ Remuneration
No explicit disclosure of directors’ pay or remuneration is provided.
Events Affecting Business
No mention of natural disasters, legal disputes, policy changes, or macroeconomic shifts in the report.
Chairman’s Statement
No Chairman’s Statement is included in the report.
Conclusion & Investor Recommendations
The audited financials of AJJ Medtech Holdings Limited for FY2025 reveal continued operating losses, significant capital deficiency, and adjustments predominantly of a presentational nature. The company’s ability to raise funds via share issuance and loans from directors suggests ongoing access to capital, but the persistent losses and negative equity highlight underlying financial weakness.
Recommendation for Current Holders: Investors currently holding AJJ Medtech should monitor the company closely for any turnaround in operational performance or capital structure improvement. Unless there is a clear path to profitability or restructuring, a cautious approach is warranted.
Recommendation for Potential Investors: Those not currently holding should exercise caution and wait for evidence of sustainable improvements in earnings, balance sheet strength, or strategic developments before considering entry.
Disclaimer: This analysis is based solely on the information disclosed in the audited financial statements for FY2025. It does not constitute investment advice. Investors should seek professional guidance and consider their own risk tolerance before making any investment decisions.
View AJJ Medtech Historical chart here
